目的：观察奥美拉唑联合雷贝拉唑治疗消化性溃疡疗效。方法：回顾性分析我院2013年6月－2015年6月收治的90例消化性溃疡患者的临床资料，根据不同治疗方案分为两组（各45例），对照组予以奥美拉唑治疗，研究组联合雷贝拉唑治疗，观察并比较两组临床疗效及不良反应情况。结果：研究组总有效率比对照组明显升高（95．55％ vs 73．33％，P＜0．05）；研究组不良反应总发生率比对照组略低（6．67％ vs 11．11％，P＞0．05）。结论：奥美拉唑联合雷贝拉唑治疗消化性溃疡疗效显著，且安全性高，值得临床推广及应用。%Objective: To observe the curative effect of the combined therapy of omeprazole and rabeprazole on peptic ulcer. Methods: A retrospective analysis was performed on the clinical data from 90 peptic ulcer patients treated by our hospital during June 2013 and June 2015 , and they were divided into two groups according to the different treatment options (each 45 cases). The control group was treated by omeprazole, and the research group was treated by combined therapy of omeprazole and rabeprazole. The clinical efficacy and adverse reactions of these two groups were observed and compared. Results: The total effective rate of the research group was higher than that of the control group ((95.55% vs 73.33%, P<0.05); the total incidence of adverse reactions of the research group was lower than that of the control group (6.67% vs 11.11%,P>0.05). Conclusion: the combined therapy of omeprazole and rabeprazole has a significant curative effect on peptic ulcer, and meanwhile, this therapy is of high safety.Therefore, it is worthwhile to be popularized and widely applied.
展开▼
